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fully satisfactory, a high recurrence rate is observed and preven-
tion strategies are not available. HPV vaccination studies have
shown high efﬁcacy against HPV-induced lesions such as GW.
Before implementing a vaccination programme, data on the inci-
dence and prevalence of GW and their associated treatment costs
are crucial. The objective of this study was to estimate these data.
METHODS: 217 specialists (gynecologists, urologists and der-
matologists) were asked to record the number of patients, aged
14–64yrs, presenting with GW between February and April
2005. The average number of patients per specialist was used to
estimate the annual number of patients. Specialists also con-
ducted a chart review of 189 previously diagnosed GW patients
visiting them in the same period. Resource use, collected from
records going back to February 2004, included visits, diagnos-
tics, medications, procedures and adverse events. The cost of
treating patients with an existing GW diagnosis was calculated
using the average cost per patient and the extrapolated annual
number of existing patients. Indirect costs were included.
RESULTS: It was estimated that there are around 57,000 new
cases and 38,000 existing cases of GW annually in Germany.
Mean treatment duration was 6.7 months, with an average of
3.2 visits to a specialist. 95% of patients had a visual exam, and
the most used diagnostics included Pap smears (25.9%), biop-
sies (25.4%) and colposcopies (24.9%). Most common therapies
were imiquimod (34.4%), electrosurgery (26.5%), laser therapy
(19.1%) and cryotherapy (17.5%). The mean annual treatment
cost per existing patient was €950. The overall estimated treat-
ment costs were €36 million per year; of which €7 million indi-
rect costs. CONCLUSION: The management of GW presents a
high burden to society that could potentially be reduced using a
quadrivalent HPV vaccine.
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OBJECTIVE: New advances in health care have shifted concern
from infectious to chronic illnesses and therefore a new empha-
sis in the assessment of satisfaction with pharmacological treat-
ment has risen. A new generic questionnaire to measure
Satisfaction with medicines is under construction. Item reduction
and factorial validity are discussed here. METHODS: The initial
instrument was composed by 36 items, arranged in 6 dimensions:
1- Efﬁcacy and symptom relieve (5 items), 2- Ease and conve-
nience (6 items), 3- Impact on HRQoL (4 items), 4- Satisfaction
with Medical Care (4 items), 5- Medication Side Effects (8
items), and 6- Overall satisfaction (9 items). Items and dimen-
sions where extracted from review of previous English instru-
ments, a panel compose by 8 experts, and 4 focus groups with
chronic patients. A convenience sample of 156 patients was used,
representative of 7 prevalent chronic pathologies (Diabetes type
II, Hypertension, Osteoarthritis, Prostate problems,
EPOC/Asthma, Depression, and Migraine). Classic psychomet-
ric theory item analysis techniques, exploratory factor analysis,
and conﬁrmatory factor analysis (to estimate accurately factor
correlations) were applied. RESULTS: The questionnaire was
reduced to a new version of 5 dimensions assessed by 14 items,
plus a dimension of Satisfaction with Medication Side Effects (3
items) to be corrected separately due to an important ﬂoor effect.
The reduced version presents an overall Cronbach alpha of
0.881, acceptable goodness of ﬁt indexes, and all factor loadings
are signiﬁcant (p < 0.001). Dimensions are well formed and cor-
relate in different degrees, but the dimension of Satisfaction with
Medical Care shows a relevant relation only with Impact on
HRQoL (r = 0.45). CONCLUSION: The questionnaire shows
good reliability and validity properties. The 5 + 1 proposed
dimensions are stable and well deﬁned in a 17-item form. Results
support that the questionnaire can be used to compute an overall
meaningful score.
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The special interest group (SIG) on Translation and Cultural
Adaptation (TCA) had its ﬁrst meeting in Hong Kong at the
2004 Annual ISOQOL meeting. The overall objective of the
TCA SIG is to identify and advance research in different areas
of interest to all parties involved in the ﬁeld of Translation and
Cultural Adaptation. Three priority areas of research were iden-
tiﬁed and organised in three subgroups: translation difﬁculties,
equivalences and methodologies. OBJECTIVES: The objectives
of subgroup one are: 1. To collect, review and analyse examples
of translations difﬁculties in the adaptation of Patient-Reported
Outcomes (PRO) measures; 2. To create a list of “good prac-
tices” for developers of questionnaires and translators, based on
the review of common translation difﬁculties and proposed solu-
tions on how to prevent them. METHODS: The group has
organised its activities in 4 steps: 1. Categorisation of difﬁcul-
ties; 2. Collection of examples of translation difﬁculties; 3.
Review of examples; and 4. Recommendations. RESULTS:
Translation difﬁculties were divided into categories according to:
1. Their position within the PRO questionnaire (i.e. Demo-
graphics, levels of education, “race”, Instructions, Items and
Response Choices); 2.The layout used, e.g. e-layout, tables, font-
related problems; and 3. Their nature: Cultural (Is the construct
to be measured relevant in the target cultures?); Conceptual and
Semantic (Do the items represent the construct deﬁnition?); Syn-
tactic; and Idiomatic. Examples of translation difﬁculties for
each category deﬁned previously and for a selection of families
and branches of languages have been collected and will be pre-
sented. Recommendations on how to prevent potential transla-
tion difﬁculties will be proposed to developers of PRO
questionnaires. CONCLUSIONS: The translation of PRO mea-
sures is a difﬁcult task. “Good practices” for the development
and translation of PRO measures should be implemented to facil-
itate the use of linguistically valid PRO measures in international
research.
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OBJECTIVES: To analyse variation in clinical injury incidence
of 7 European countries, and to determine whether using differ-
ent injury indicators can minimize the bias in clinical injury 
incidence data and increase the comparability of the data.
